Abstract:Introduction: Chagas disease, caused by chronic infection with the protozoan parasite Trypanosoma cruzi, affects 6-7 million people worldwide. The major clinical manifestation of Chagas disease is chronic Chagasic cardiomyopathy (CCC), which encompasses a spectrum of symptoms including arrhythmias, hypertrophy, dilated cardiomyopathy, heart failure, and sudden death. Current treatment is limited to two antiparasitic drugs, benznidazole (BNZ) and nifurtimox, but both have limited efficacy to halt the progression of CCC. We developed a vaccine-linked chemotherapy strategy using our vaccine consisting of recombinant Tc24-C4 protein and a TLR-4 agonist adjuvant in a stable squalene emulsion, in combination with low dose benznidazole treatment. We previously demonstrated in acute infection models that this strategy parasite specific immune responses, and reduced parasite burdens and cardiac pathology. Here, we tested our vaccine-linked chemotherapy strategy in a mouse model of chronic T. cruzi infection to evaluate the effect on cardiac function. Methods: Female BALB/c mice infected with 500 blood form T. cruzi H1 strain trypomastigotes were treated beginning 70 days after infection with a low dose of BNZ and either low or high dose of vaccine, in both sequential and concurrent treatments streams. Control mice were untreated, or administered only one treatment. Cardiac health was monitored throughout the course of treatment by echocardiography and electrocardiograms. Approximately 8 months after infection, endpoint histopathology was performed to measure cardiac fibrosis and cellular infiltration. Results: Vaccine-linked chemotherapy improved cardiac function as evidenced by amelioration of altered left ventricular wall thickness, left ventricular diameter, as well as ejection fraction and fractional shortening by approximately 4 months of infection, corresponding to two months after treatment was initiated. At study endpoint, vaccine-linked chemotherapy reduced cardiac cellular infiltration, and induced significantly increased antigen specific IFN-γ and IL-10 release from splenocytes, as well as a trend toward increased IL-17A. Discussion: These data suggest that vaccine-linked chemotherapy ameliorates changes in cardiac structure and function induced by infection with T. cruzi. Importantly, similar to our acute model, the vaccine-linked chemotherapy strategy induced durable antigen specific immune responses, suggesting the potential for a long lasting protective effect. Future studies will evaluate additional treatments that can further improve cardiac function during chronic infection.

Harnessing RNA Technology to Advance Therapeutic Vaccine Antigens against Chagas Disease

Challenges and advancements in the development of vaccines and therapies against Chagas disease

Treatments and the Perspectives of Developing a Vaccine for Chagas Disease

Challenges in Chagas Disease Drug Development

Vaccine-linked chemotherapy improves cardiac structure and function in a mouse model of chronic Chagas disease

What are the translational challenges associated with Chagas disease drug discovery?

Alternative Approaches for the Treatment of Chagas Disease

Molecular tools to regulate gene expression in Trypanosoma cruzi

Protective Efficacy of the Epitope-Conjugated Antigen N-Tc52/TSkb20 in Mitigating Trypanosoma cruzi Infection through CD8+ T-Cells and IFNγ Responses

Vaccination with parasite-specific TcTASV proteins combined with recombinant baculovirus as a delivery platform protects against acute and chronic Trypanosoma cruzi infection

A prophylactic α-Gal-based glycovaccine effectively protects against murine acute Chagas disease

Intranasal Trans-Sialidase Vaccine Mitigates Acute and Chronic Pathology in a Preclinical Oral Chagas Disease Model

Nanomedicines against Chagas disease: a critical review

Tackling the Challenges of human Chagas Disease: a Comprehensive Review of Treatment Strategies in the Chronic Phase and Emerging Therapeutic Approaches

Trypanosoma cruzi antigen detection in blood to assess treatment efficacy and cure in mice models of Chagas disease

Treatment options for Chagas Disease: a systematic review and meta-analysis applied to the preclinical studies using animal models

Characterization and Stability of Trypanosoma cruzi 24-C4 (Tc24-C4), a Candidate Antigen for a Therapeutic Vaccine Against Chagas Disease

Exploring the performance of Escherichia coli outer membrane vesicles as a tool for vaccine development against Chagas disease

Discovery and Genetic Validation of Chemotherapeutic Targets for Chagas' Disease

Animal models of Chagas disease and their translational value to drug development

Recombinant proteins as promising antigens applied to the immunodiagnosis of Chagas disease: a scoping review